190 related articles for article (PubMed ID: 34003452)
21. Menstrual disorders associated with sirolimus treatment.
Triana P; López-Gutierrez JC
Pediatr Blood Cancer; 2021 Mar; 68(3):e28867. PubMed ID: 33369022
[TBL] [Abstract][Full Text] [Related]
22. Treatment of superficial vascular anomalies with topical sirolimus: A multicenter case series.
Dodds M; Tollefson M; Castelo-Soccio L; Garzon MC; Hogeling M; Hook K; Boull C; Maguiness S
Pediatr Dermatol; 2020 Mar; 37(2):272-277. PubMed ID: 31957126
[TBL] [Abstract][Full Text] [Related]
23. Sirolimus in the Treatment of Vascular Anomalies.
Triana P; Dore M; Cerezo VN; Cervantes M; Sánchez AV; Ferrero MM; González MD; Lopez-Gutierrez JC
Eur J Pediatr Surg; 2017 Feb; 27(1):86-90. PubMed ID: 27723921
[No Abstract] [Full Text] [Related]
24. Fibroadipose vascular anomaly treated with sirolimus: Successful outcome in two patients.
Erickson J; McAuliffe W; Blennerhassett L; Halbert A
Pediatr Dermatol; 2017 Nov; 34(6):e317-e320. PubMed ID: 29144050
[TBL] [Abstract][Full Text] [Related]
25. Treatment of Lymphatic Malformations with the mTOR Inhibitor Sirolimus: A Systematic Review.
Wiegand S; Wichmann G; Dietz A
Lymphat Res Biol; 2018 Aug; 16(4):330-339. PubMed ID: 29924669
[TBL] [Abstract][Full Text] [Related]
26. Severe adverse events during sirolimus "off-label" therapy for vascular anomalies.
Rössler J; Baselga E; Davila V; Celis V; Diociaiuti A; El Hachem M; Mestre S; Haeberli D; Prokop A; Hanke C; Loichinger W; Quéré I; Baumgartner I; Niemeyer CM; Kapp FG
Pediatr Blood Cancer; 2021 Aug; 68(8):e28936. PubMed ID: 33580918
[TBL] [Abstract][Full Text] [Related]
27. Preliminary results of the European multicentric phase III trial regarding sirolimus in slow-flow vascular malformations.
Seront E; Van Damme A; Legrand C; Bisdorff-Bresson A; Orcel P; Funck-Brentano T; Sevestre MA; Dompmartin A; Quere I; Brouillard P; Revencu N; De Bortoli M; Hammer F; Clapuyt P; Dumitriu D; Vikkula M; Boon LM
JCI Insight; 2023 Nov; 8(21):. PubMed ID: 37937645
[TBL] [Abstract][Full Text] [Related]
28. [Our experience with sirolimus for the treatment of complicated vascular anomalies].
Giménez-Aleixandre C; Méndez-Aguirre NA; Martínez-Menchón T; Girón Vallejo Ó; Fernández-Ibieta M; Ferri-Ñíguez B; Villamil V; Sánchez-Sánchez Á; Montoya-Rangel CA; Hernández-Bermejo JP
Cir Pediatr; 2019 Jan; 32(1):28-33. PubMed ID: 30714698
[TBL] [Abstract][Full Text] [Related]
29. Successful Treatment of Fibro-Adipose Vascular Anomaly with Sirolimus.
Wang Z; Yan H; Ding Y; Gong Y; Ma Y; Yao W; Li K
J Pediatr Surg; 2023 Jul; 58(7):1337-1341. PubMed ID: 36898877
[TBL] [Abstract][Full Text] [Related]
30. Effect of sirolimus on coagulopathy of slow-flow vascular malformations.
Mack JM; Verkamp B; Richter GT; Nicholas R; Stewart K; Crary SE
Pediatr Blood Cancer; 2019 Oct; 66(10):e27896. PubMed ID: 31250546
[TBL] [Abstract][Full Text] [Related]
31. Topical sirolimus 0.1% for treating cutaneous microcystic lymphatic malformations in children and adults (TOPICAL): protocol for a multicenter phase 2, within-person, randomized, double-blind, vehicle-controlled clinical trial.
Leducq S; Caille A; Barbarot S; Bénéton N; Bessis D; Boccara O; Bursztejn AC; Chiaverini C; Dompmartin A; Droitcourt C; Gissot V; Goga D; Guibaud L; Herbreteau D; Le Touze A; Léauté-Labrèze C; Lorette G; Mallet S; Martin L; Mazereeuw-Hautier J; Phan A; Plantin P; Quéré I; Vabres P; Bourgoin H; Giraudeau B; Maruani A;
Trials; 2019 Dec; 20(1):739. PubMed ID: 31847908
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of sirolimus in the treatment of vascular anomalies: A systematic review.
Freixo C; Ferreira V; Martins J; Almeida R; Caldeira D; Rosa M; Costa J; Ferreira J
J Vasc Surg; 2020 Jan; 71(1):318-327. PubMed ID: 31676179
[TBL] [Abstract][Full Text] [Related]
33. Successful Treatment of a Complex Vascular Malformation With Sirolimus and Surgical Resection.
Goldenberg DC; Carvas M; Adams D; Giannotti M; Gemperli R
J Pediatr Hematol Oncol; 2017 May; 39(4):e191-e195. PubMed ID: 27820120
[TBL] [Abstract][Full Text] [Related]
34. Sirolimus for management of complex vascular anomalies - A proposed dosing regimen for very young infants.
Czechowicz JA; Long-Boyle JR; Rosbe KW; Mathes EF; Frieden IJ; Shimano KA
Int J Pediatr Otorhinolaryngol; 2018 Feb; 105():48-51. PubMed ID: 29447818
[TBL] [Abstract][Full Text] [Related]
35. Infectious complications of vascular anomalies treated with sirolimus: A systematic review.
Kalbfell R; Cohen-Cutler S; Grisham E; Bereitschaft C; Borst AJ; Green AM; Willis DN; Yaeger L; Blatt J; Sisk BA
Pediatr Blood Cancer; 2024 Jan; 71(1):e30758. PubMed ID: 37933207
[TBL] [Abstract][Full Text] [Related]
36. Oral and Topical Sirolimus for Vascular Anomalies: A Multicentre Study and Review.
Sandbank S; Molho-Pessach V; Farkas A; Barzilai A; Greenberger S
Acta Derm Venereol; 2019 Oct; 99(11):990-996. PubMed ID: 31304557
[TBL] [Abstract][Full Text] [Related]
37. Effects of physiotherapy combined with sirolimus in a patient with vascular malformation: A case report.
Akbayrak T; Orhan C; Baran E; Kaya S; Coskun G; Varan A
Turk J Pediatr; 2016; 58(2):203-207. PubMed ID: 27976563
[TBL] [Abstract][Full Text] [Related]
38. Response of Blue Rubber Bleb Nevus Syndrome to Sirolimus Treatment.
Salloum R; Fox CE; Alvarez-Allende CR; Hammill AM; Dasgupta R; Dickie BH; Mobberley-Schuman P; Wentzel MS; Chute C; Kaul A; Patel M; Merrow AC; Gupta A; Whitworth JR; Adams DM
Pediatr Blood Cancer; 2016 Nov; 63(11):1911-4. PubMed ID: 27273326
[TBL] [Abstract][Full Text] [Related]
39. Magnitude and relevance of change in health-related quality of life in patients with vascular malformations treated with sirolimus.
Harbers VEM; Bouwman FCM; van Rijnsoever IMP; Verhoeven BH; van der Vleuten CJM; Schultze Kool LJ; de Laat PCJ; van der Horst CMAM; Kievit W; Te Loo DMWM
Front Med (Lausanne); 2023; 10():1155476. PubMed ID: 37153086
[TBL] [Abstract][Full Text] [Related]
40. Effects of sirolimus in the treatment of unresectable infantile hemangioma and vascular malformations in children: A single-center experience.
Cho YJ; Kwon H; Kwon YJ; Kim SC; Kim DY; Namgoong JM
J Vasc Surg Venous Lymphat Disord; 2021 Nov; 9(6):1488-1494. PubMed ID: 33836285
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
